Mayo Clinic's approach

Mayo Clinic's approach to precision medicine for breast cancer is built on:

A multidisciplinary team

The team approach is built into Mayo Clinic's structure. You will have a lead physician who coordinates your care with a team that may include internal medicine breast specialists from the Breast Clinic, medical oncologists, breast radiologists, radiation oncologists, surgeons (breast and plastic), psychologists, pathologists, laboratory professionals, nurse practitioners, physician assistants, nurses, genetic counselors, bioinformaticians, physical therapists, researchers, pharmacists and others.

An individualized approach

Your care team works with you to develop an individualized plan that meets your needs. They will talk with you about the possibility of genetic testing, which, along with your family medical history, laboratory tests and physical examination, may help your medical team understand how your cancer developed and how you might respond to various treatments. Genetic testing is useful in many ways, including:

  • Avoiding ineffective hormonal therapy. Mayo Clinic researchers have identified a blood test that may indicate whether you will respond to the breast cancer drug tamoxifen. This precision approach enables doctors to prescribe another medication for patients who may not respond to tamoxifen.
  • Sequencing the tumor. At Mayo Clinic tumor sequencing is increasingly used to select treatment for patients with breast cancer. For women whose treatment isn't working, this type of test can help explain why and indicate a drug that might work better. It involves doing a tumor biopsy, analyzing the tissue genetically and then basing a recommendation for treatment on the results of that analysis.
  • Tracking variants of uncertain significance. It's common for a genetic test result to indicate that a genetic mutation is a variant of uncertain significance (VUS). When this result is from a test done on the genes you're born, it doesn't indicate clearly whether you are at increased risk of cancer. Nor does it tell us if your body uses the medications in question correctly. When this result is from a test done on the cancer cells, it may reveal gene mutations for which we don't have specific drugs to attack the cancer.

    Mayo Clinic is the first medical group in the world with an up-to-date registry on VUS results for the breast cancer genes BRCA1 and BRCA2. This registry helps Mayo Clinic researchers determine which VUS results cause diseases.

Genomics in everyday patient care

Because of its rich history of genomic research and its large clinical practice, Mayo Clinic is at the forefront of efforts to integrate precision medicine into clinical care. It is among the few major medical institutions to include pharmacogenomics data in its electronic medical record (EMR) system. In addition, the clinic has invested in a complete upgrade of its EMR system so that it's ready for the rapid expansion of precision medicine into routine medical care.

Familial Cancer Program

Mayo Clinic offers people with breast cancer the opportunity to participate in its Familial Cancer Program, which helps identify people at increased risk of breast cancer related to family history.

In this program, a team of doctors, genetic counselors and nurses evaluates individuals and their families to determine potential cancer risk. The team develops a customized cancer-screening plan for families who have increased risks of developing cancer. Consultations are offered to people who have been diagnosed with cancer and to family members who haven't had cancer.

Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Jacksonville, Florida, and Mayo Clinic in Phoenix/Scottsdale, Arizona, are ranked among the Best Hospitals for cancer by U.S. News & World Report.

Expertise and rankings

Mayo Clinic is a leader in the emerging field of precision medicine. And breast cancer is among the first areas in which the clinic is making this approach available to patients.

Innovation and research

Mayo Clinic is making new options available to people at risk of breast cancer and those who have received a diagnosis of breast cancer. These advances are built on the clinic's rich history in advancing the science of using genomics to better predict, diagnose and treat disease. Mayo Clinic activities include:

  • Launching a clinical trial for women with metastatic, estrogen receptor-positive cancer in which all participants receive tumor sequencing with interpretation.
  • Identifying new DNA sequences associated with breast cancer, which is key to finding drugs that target cancer cells.
  • Refining a panel of genes that likely play a role in the development of breast cancer, which may help doctors more accurately identify members of families who are at increased risk of breast cancer.
  • Doing advanced (phase II) clinical trials of endoxifen, a drug developed by Mayo Clinic researchers to help people who don't respond to standard hormonal therapies, including aromatase inhibitors, fulvestrant and tamoxifen.

Nationally recognized expertise

Mayo Clinic has been chosen to serve as the nation's biobank for precision medicine. It will be the home of the National Precision Medicine Initiative Cohort Program Biobank, an NIH-funded biobank that will hold a research repository of biologic samples. The biobank will be a major force in advancing precision medicine and contributing to research and improved health care.

In addition, Mayo Clinic's precision medicine researchers joined Nobel Prize winners and other worldwide leaders as featured speakers at the 10th International Society for Applied Biological Sciences Conference. This conference is considered one of the most important events of the year in precision medicine.

Mayo Clinic's other leadership roles in precision medicine include:

Center for Individualized Medicine

The Mayo Clinic Center for Individualized Medicine explores and advances personalizing patient care through the application of genomic science and applying new therapies targeted to a person's genetic mutations.

The center hosts an annual genomics conference where international researchers and experts in the rapidly changing field of precision medicine share their discoveries.

Comprehensive cancer center

Mayo Clinic Comprehensive Cancer Center meets strict standards for a National Cancer Institute comprehensive cancer center, which recognizes scientific excellence and a multidisciplinary approach to cancer prevention, diagnosis and treatment.

Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Jacksonville, Florida, and Mayo Clinic in Phoenix/Scottsdale, Arizona, are ranked among the Best Hospitals for cancer by U.S. News & World Report.

Learn more about Mayo Clinic's precision medicine and cancer center expertise and rankings.

More information about billing and insurance:

Mayo Clinic in Arizona, Florida and Minnesota

Mayo Clinic Health System

Oct. 19, 2021
  1. Alisertib with or without fulvestrant in treating patients with locally advanced or metastatic, endocrine-resistant breast cancer. Accessed Sept. 9, 2017.
  2. BRCA1 and BRCA2: Cancer risk and genetic testing. National Cancer Institute. Accessed June 13, 2017.
  3. Luo K, et al. A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination. Genes & Development. 2016;30:1.
  4. Van Poznak C, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Oncology Practice. 2015;11:514.
  5. Goetz MP (expert opinion). Mayo Clinic, Rochester, Minn. Sept. 26, 2017.
  6. Gradishar WJ, et al. Invasive breast cancer version 1.2016. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2016;14:324.
  7. Studying genes. National Institute of General Medical Sciences. Accessed June 13, 2017.
  8. AskMayoExpert. Genetic testing for BRCA1 and BRCA2 mutations. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2017.
  9. Mayo Clinic to be home of National Precision Medicine Initiative (PMI) Cohort Program Biobank. News release, Mayo Clinic, Rochester, Minnesota. Sept. 26, 2017.
  10. AskMayoExpert. Breast cancer. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
  11. Goetz MP, et al. Tumor sequencing and patient-derived xenografts in the neoadjuvant treatment of breast cancer. Journal of the National Cancer Institute. 2017;109:djw306. Accessed June 12, 2017.
  12. Couch FJ, et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncology. 2017;3:1190.
  13. Hamburg MA, et al. The path to personalized medicine. New England Journal of Medicine. 2010;363:301.
  14. Electronic Medical Records and Genomics (eMERGE) Network. National Human Genome Research Institute. Accessed June 12, 2017.
  15. Pritchard DE, et al. Strategies for integrating personalized medicine into healthcare practice. Personalized Medicine. 2017;14:141.
  16. The Personalized Medicine Coalition. Personalized Medicine at FDA: 2016 Progress Report. Accessed June 13, 2017.
  17. Peshkin BN. Genetic counseling and testing for hereditary breast and ovarian cancer. Accessed June 13, 2017.
  18. Raby BA. Personalized medicine. Accessed June 13, 2017.
  19. Liu T, et al. CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. Nature Communication. 2017;8:13923.
  20. Ingle JN, et al. Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomics basis for the response of breast cancer patients to aromatase inhibitor therapy. Cancer Research. 2016;76:7012.
  21. Ingle JN, et al. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids. 2015;99:32.
  22. Goetz MP, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clinical Cancer Research. 2013;19:500.
  23. Goetz MP, et al. First-in-human phase I study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer. Journal of Clinical Oncology. In press. Accessed Oct. 17, 2017.
  24. D'Assoro AB, et al. The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in Era(+) breast cancer cells. Oncogene. 2014;33:599.

Precision medicine for breast cancer